期刊名称：AGING-US
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
In aging research, evidence emerges that aging is controlled by genetic mechanisms involving signal transduction pathways highly conserved from yeast to mammals. Hyper-stimulation of certain signaling pathways drives the aging process and is involved in cell senescence and age-related disease. Modulation of DNA-damage response, sirtuins and stress-response, insulin-activated pathways, nutrient-sensing pathways, p53, FOXO and PTEN extends life span. And calorie restriction extends life span by modulating the same signaling pathways. This provides a potential means of pharmacologic intervention to extend life span and treat age-related diseases. This new journal welcomes scientists in all disciplines, not only those in traditional gerontology.
AGING publishes high-impact research papers of general interest and biological significance in all fields of aging research including but not limited to cellular senescence, DNA damage and repair, organismal aging, age-related diseases, genetic control of aging from yeast to mammals, regulation of longevity, evolution of aging, anti-aging strategies and drug development and especially the role of signal transduction pathways in aging and potential approaches to modulate these signaling pathways to extend lifespan.
AGING covers (in addition to traditional topics on aging) many other topics including cellular and molecular biology (regulation of translation, cell growth, death and autophagy, mitochondria, DNA damage and repair, microRNAs, stem cells), human age-related diseases, pathology in model organisms, cancer and first of all signal transduction pathways (p53, sirtuins, PI-3K/AKT/mTOR and so on) and approaches to modulate these signaling pathways.
AGING is indexed by PubMed/Medline, PubMed Central, ISI/Thomson and Scopus.
AGING is abbreviated by indexes: by PubMed - Aging (Albany NY); by ISI/Thomson - Aging-US; by Scopus - Aging.
Instructions to Authors
I. Unique Aims and Scope
AGING journal publishes high-impact research papers of general interest and biological significance in all fields of aging research including but not limited to cellular senescence, organismal aging, age-related diseases, DNA damage response and repair, genetic control of aging from yeast to mammals, regulation of longevity, evolution of aging, anti-aging strategies and drug development and especially the role of signal transduction pathways in aging and potential approaches to modulate these signaling pathways to extend lifespan.
The basic criterion for considering papers is their impact on aging research.
In addition to primary research articles in three formats (Priority Reports, Research Articles, Theory Articles), AGING publishes Reviews, Mini-reviews, Perspectives, Commentaries and Letters to the Editor.
All submissions are initially evaluated in depth by the editors. Papers that do not conform to the general criteria for publication will be returned to the authors without detailed review, typically within 2-4 days. Otherwise, manuscripts will be sent to 2-3 reviewers who have agreed in advance to assess the paper rapidly. The editors will make every effort to reach decisions on these papers within 3 weeks of the submission date. If revisions are a condition of publication, we generally allow 3 months for revisions and consider only one revised version of the paper.
II. Submitting an Article
Submit an article by e-mail as an attachment to: papers@impactaging.com
var ss = document.getElementById("empapers");
var st = "papers";
st+="@";
st+="impactaging";
st+=".";
st+="com";
ss.innerHTML=st;
ss.setAttribute("href", "mailto:"+st);
III. Editorial Policies
Authorship
The corresponding author is responsible for ensuring that all appropriate contributors are listed as authors and that all authors have agreed to the manuscript’s content and its submission to AGING. In a case where we become aware of an authorship dispute, authorship must be approved in writing by all of the parties.
Conflict of Interest
The authors should indicate conflicts of interests and sources of financial support. Conflict of interest exists when an author (or the authors institution), reviewer, or editor has financial or personal relationships that inappropriately influence (bias) his or her actions. The potential for conflict of interest can exist whether or not an individual believes that the relationship affects his or her scientific judgment. Financial relationships (such as employment, consultancies, stock ownership, honoraria, paid expert testimony) as well as personal relationships and academic competition must be declared. The authors declare conflicts of interests and sources of financial support as acknowledgment.
Informed consent
Patients have a right to privacy that should not be infringed without informed consent. Identifying information should not be published unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. A patient who is identifiable must be shown the manuscript to be published. Identifying details should be omitted if they are not essential. If identifying details are altered, editors should be informed. When informed consent has been obtained it should be indicated in the published article as: Informed consent has been obtained.
Human and animal rights. Ethical statment
All research involving human participants must have been approved by the authors' institutional review board or equivalent committee(s) and that board must be named by the authors in the manuscript. For research involving human participants, informed consent must have been obtained (or the reason for lack of consent explained, e.g. the data were analyzed anonymously) and all clinical investigation must have been conducted according to the principles expressed in the Declaration of Helsinki. Authors should submit a statement from their ethics committee or institutional review board indicating the approval of the research. All animal work must have been conducted according to relevant national and international guidelines. In accordance with the recommendations of the Weatherall report, "The use of non-human primates in research." we specifically require authors to include details of animal welfare and steps taken to ameliorate suffering in all work involving non-human primates. At the beginning of the Methods section of your manuscript (with the subheading Ethics Statement) enter: Investigation has been conducted in accordance with the ethical standards and according to the Declaration of Helsinki and according to national and international guidelines and has been approved by the authors' institutional review board.
Distribution of Materials and Data
One of the terms of publishing in AGING is that authors be willing to distribute any materials and protocols used in the published experiments to qualified researchers for their own use. If there are restrictions to the availability of any materials, data, or information, these must be disclosed in the cover letter and the Experimental Procedures section of the manuscript at the time of submission.
Nucleic acid and protein sequences, macromolecular structures determined by X-ray crystallography (along with structure factors), and microarray data must be deposited in the appropriate public database and must be accessible without restriction from the date of publication. An entry name or accession number must be included as the last paragraph of the Experimental Procedures section in the final version of the manuscript. Microarray data should be MIAME compliant (for guidelines see http://www.mged.org/Workgroups/MIAME/miame.html).
Copyright and License Policies
Upon submission of an article, authors must agree to abide by an open-access license. The license permits any user to download, print out, extract, and archive articles.
Upon publication, AGING is intended to deposit all articles in PubMed Central. This complies with the policies of funding agencies, such as the National Institutes of Health in the United States, the Wellcome Trust and the Research Councils in the United Kingdom, and the Deutsche Forschungsgemeinschaft in Germany, which request or require deposition of the published articles that they fund into publicly available databases.
In most cases, appropriate attribution can be provided by simply citing the original article. For any reuse or redistribution of a work, the author must also make clear the license terms under which the work was published.
This broad license was developed to facilitate open access to, and free use of, original works of all types. Applying this standard license to your own work will ensure your right to make your work freely and openly available.
Interaction with Members of the Press for Papers in Press
Authors are free to talk with the press starting on the day of acceptance. We also allow authors to discuss their work in press with other scientific journals for purposes of coverage in review material. If your press office wishes to issue a press release, they may do that.
Presubmission Inquiries
If you would like editorial input on whether your paper might be a strong candidate for consideration at AGING, you can send a presubmission inquiry. This should include an abstract plus a brief description of the results and an explanation of the interest and significance to the broad readership of AGING and be emailed to editors@impactaging.com. We try to respond to these within 1-2 days.
IV. Studies Involving Humans and Animals: Guidelines for Specific Study Designs
We follow the WHO definition of a clinical trial. "A clinical trial is any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes. Interventions include but are not restricted to drugs, cells and other biological products, surgical procedures, radiologic procedures, devices, behavioural treatments, process-of-care changes, preventive care, etc"
AGING supports the position of the International Committee of Medical Journal Editors (ICMJE) on trial registration. All trials initiated after 1 July 2005 must be registered prospectively in a publicly accessible registry (i.e., before patient recruitment has begun), or they will not be considered for publication. For trials initiated before 1 July 2005, all trials must be registered before submission to our journals. See the ICMJE faq on trial registration on trial registration for further details. The WHO's list of approved registries is listed here http://www.who.int/ictrp/network/list_registers/en/index.html.
Authors of randomized controlled trials must adhere to the CONSORT reporting guidelines appropriate to their trial design. Please check the CONSORT statement Web site for information on the appropriate guidelines for specific trial types. Before the paper can enter peer review authors must: 1) name in the paper trial registry, trial registration number, and IRB and 2) provide a copy of the trial protocol and a completed CONSORT checklist as supporting files. The CONSORT flow diagram must be included as Figure 1. Any deviation from the trial protocol must be explained in the paper. Authors must explicitly discuss informed consent in their paper, and AGING reserves the right to ask for a copy of the patient consent form. Information on statistical methods or participants beyond what is indicated in the CONSORT statement should be reported in the Methods section.
Systematic Reviews and Meta-Analyses of Randomized Controlled Trials
Reports of meta-analyses of randomized controlled trials (RCTs) should use the QUOROM statement as a guide (Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, et al. [1999] Improving the quality of reports of meta-analyses of randomized controlled trials: The QUOROM statement. Lancet 354: 1896; 1900) and include a copy of the QUOROM checklist (27KB PDF).
Diagnostic Studies
Reports of studies of diagnostic accuracy should conform to the STARD requirements.
Epidemiological Studies
For reports of epidemiological studies, you should consult the STROBE initiative.
Microarray Experiments
Reports of microarray experiments should conform to the MIAME guidelines and the data from the experiments must be deposited in a publicly accessible database.
Human and Animal Research
All research involving humans and animals must have been approved by the authors' institutional review board or equivalent committee and that board named by the authors. In the case of human participants, informed consent must have been obtained and all clinical investigation must have been conducted according to the principles expressed in the Declaration of Helsinki. Authors should submit a statement from the ethics committee or institutional review board indicating their approval of the research. We also encourage authors to submit a sample of a patient consent form and may require submission of completed forms on particular occasions.
For studies involving humans categorized by race/ethnicity, age, disease/disabilities, religion, sex/gender, sexual orientation, or other socially constructed groupings, authors should, as much as possible:
make explicit their methods of categorizing human populations;
define categories in as much detail as the study protocol allows;
justify their choices of definitions and categories, including for example whether any rules of human categorization were required by their funding agency;
explain whether (and if so, how) they controlled for confounding variables such as socioeconomic status, nutrition, environmental exposures, etc.
In addition, outmoded terms and potentially stigmatizing labels should be changed to more current, acceptable terminology. Examples: "Caucasian" should be changed to "white" or "of [Western] European descent" (as appropriate); "cancer victims" should be changed to "patients with cancer".
V. Research Article Formats
Priority Reports
Brief Advances present conceptual advances of unusual significance. Priority Reports should be as concise as possible and written in a style that is accessible to a broad readership. The total word count must be under 4,000 words, and there should be no more than 6 figures and/or tables. Additional items may be published online as Supplemental Data at the discretion of the editors.
Research Articles
The total word count must be under 4,000 words, and there should be no more than 8 figures and/or tables. Additional items may be published online as Supplemental Data (not more than 4 figures and Tables) at the discretion of the editors. Papers exceeding these size will be considered as oversized papers and will be subject to additional page charges: $ 20 for every additional page (above the 4000 word limit) and 50$ for every additional figure/table.
Theory Articles
The Theory format is intended for articles that main conclusions are based on computational, theoretical, or analytical approaches and/or re-interpretation of existing published data. Theory article will explain previously unexplained phenomena, provide mechanism for observations, integrate separate facts in one model, to substitute general rules for thousands of independent facts. The conclusions must be novel compared with otherwise published paradigms. The authors may include additional experiments to support points that lack already published supporting data. Theory articles must also suggest experimentally testable predictions. They follow the same format and length guidelines as Research articles.
Editorials
Will be generally invited but authors may suggest an editorial content.
Commentaries
A brief topical reviews of recent scientific advances. Commentaries may contain clarifications, new interpretations or disagreements with current paradigm. May include both published and unpublished own data to clarify the point.
Mini-reviews
Will be generally invited but authors may suggest a topic focused on the authors’ recent publications of high impact in aging research.
Review Articles
Will be generally invited but authors may suggest a Review on a broad topic of general interest.
VI. Article Organization
Cover Letter
Each submission should be accompanied by a cover letter, which should contain a brief explanation of the work impact. A cover letter may contain suggestions for appropriate reviewers.
Research articles generally contain the following sections in this order: Title, Authors, Affiliations, Contact Information, Running title, Key words (6-7), Abstarct, Introduction, Results, Discussion, Methods, Acknowledgements, References, Figure and Table Legends, Figures and Tables, Supplemental Data. The text (Title through Legends) should be provided as one document, which may also contain the Tables. Figures should be provided separately. Supplemental Data should be provided separately.
The total word count of the text, including all sections and supplemental data, should not exceed 8000 words for research articles. An article may contain up to 10 figures and/or tables. Gene symbols should be italicized; protein products of the loci are not italicized. Nonstandard abbreviations should be defined when first used in the text. Use of abbreviations should be kept at a minimum. Manuscript file types that we can accept for submission include Word and RTF.
The text should be double spaced and pages should be numbered. Although summaries need to be entered as text files separate from the body of the manuscript during the online submission process, they should also be included within the manuscript file as usual.
Manuscripts that do not conform to the format guidelines may be returned to the authors for reformatting.
Preparation of Specific Sections
Title
The title should convey the conceptual significance of the paper to a broad readership.
Authors/Affiliations
Author names should be spelled out rather than set in initials. Authors should be footnoted to corresponding affiliations. Affiliations should contain the following core information: department(s)/subunit(s); institution; city, state/region, postal code; country.
Contact
The contact line should include the email address and phone/fax numbers of the corresponding author. The published corresponding author is responsible for ensuring adherence to all editorial and submission policies and for any communications that may result post-publication.
Additional Footnotes
Footnotes are only allowed on page 1 of the text (and in tables). They may include a present address or statement of equal contribution to the manuscript.
Abstract
The Abstract consists of a single paragraph of fewer than 200 words. It should clearly convey the conceptual advance and significance of the work to a broad readership. References should not be cited in the Summary.
Introduction
The Introduction should be succinct, with no subheadings, and should present the background information necessary to provide a biological context for the results.
Results
This section should be divided with subheadings.
Discussion
The Discussion should explain the significance of the results and place them into a broader context. This section may in some cases be combined with the Results section.
Methods
The Methods section needs to include sufficient detail so that readers can understand how the experiments were done, and so that all procedures can be repeated, in conjunction with cited references. This section should also include a description of any statistical methods employed in the study.
Acknowledgments
This section may acknowledge contributions from non-authors, list funding sources, and should include a statement of any conflict of interests.
References
The list of references should be numbered consecutively according to the first time mentioned within the article. Cite only the number assigned to the reference: For example, according to Campisi [1]. References should include only articles that are published or in press. Unpublished data, submitted manuscripts, abstracts, and personal communications should be cited within the text only. Personal communication should be documented by a letter of permission. Submitted articles should be cited as unpublished data, data not shown, or personal communication. Note: "et al." should only be used after 13 authors. Please use the following style for references:
Article in a periodical:
1. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol. 2007; 8: 729-740.
Article in a book:
King SM. (2003). Dynein motors: Structure, mechanochemistry and regulation. In Molecular Motors, Schliwa M, ed. (Weinheim, Germany: Wiley-VCH Verlag GmbH), pp. 45-78.
An entire book:
Cowan WM, Jessell TM and Zipursky SL. (1997). Molecular and Cellular Approaches to Neural Development (New York: Oxford University Press).
VII. Figures, Tables and Supplemental Data
Figure Legends
Legends should be included in the submitted manuscript as a separate section. Each figure legend should have a brief title that describes the entire figure without citing specific panels, followed by a description of each panel. For any figures presenting pooled data, the measures should be defined in the figure legends (for example, data are represented as mean +/- SEM).
Tables
When creating a table, please use the Microsoft Word table function and do not place an Excel table in a Word document. Word tables should not be tab or space delineated and should not use color. Tables should include a title, and footnotes and/or legend should be concise. Include tables in the submitted manuscript as a separate section. Tables not created using the Microsoft Word table function will need to be revised by the author.
Supplemental Data
Supplemental data are restricted to items that are directly pertinent to the conclusions of the paper. Editors reserve the right to limit the scope and length of Supplemental Data. Supplemental Data should be provided with the original submission. Please follow the digital figure guidelines below for preparing figures. In general, supplemental files (movies, databases, tables, etc.) must each be less than 10 MB. All figures and tables should have titles and legends. In general, every attempt should be made to submit the Supplemental Data in a composite Word file.
Supplemental Movies
Supplemental movies may be submitted as .mov, .avi, .mpeg, or .gif files.
Figure Organization, Formats, and Style
Each figure must be assembled into one file that prints onto one 8 1/2 x 11 page. Please do not include separate panels on multiple pages. Micrographs should be provided with a scale bar, if appropriate, instead of magnification.
Acceptable Image Formats for Online Submission:
TIFF (.tif)
JPEG (.jpg) use maximum quality
PowerPoint (.ppt)
Encapsulated Postscript Files (.eps)
Postscript Files (.ps)
Encapsulated Postscript Files (.eps)
As with all vector files (Adobe Illustrator, etc.), when saving as .eps, please be sure to embed all fonts or convert to outlines or paths.
Postscript Files (.ps)
There are many different drawing programs, not all of them supported by the software we use. From almost all of these programs, you should be able to produce a postscript file. When printing, select to print to a (postscript) file, rather than printing by default to a printer. The image must be in portrait orientation. Please be sure to embed all fonts when you save as postscript.
Resolution Requirements
Images composed of lines and text, which does not contain tonal or shaded areas should have resoluton 900-1200 dpi.
For black and white photographs, and images that contain halftone + text or line art elements, the resolution of your file should be 500-900 dpi.
A continuous tone photograph, which contains no text, should have resolution 300-900 dpi. Please note that figures should meet these resolution numbers at their approximate print sizes.
Color Images
We encourage authors to use colors that can be distinguished by color-blind readers. Please submit your figures in RGB or grayscale -- do not convert your files to CMYK. This will optimize their appearance online. If possible, embed the ICC profile.
Line Weights
Any lines in the graphic should be no smaller than 2 points width, when viewed at actual size.
Editorial Board
Editors-in-Chief
Mikhail V. Blagosklonny Roswell Park Cancer Institute, Buffalo, NY, USA
Judith Campisi Buck Institute for Age Research, Novato, CA, USA
David A.Sinclair Harvard Medical School, Boston, MA, USA
Editorial board
Frederick Alt Harvard Medical School, Boston, MA, USA
Vladimir Anisimov Petrov Institute of Oncology, St.Petersburg, Russia
Andrzej Bartke Southern Illinois University, Springfield, IL, USA
Elizabeth H. Blackburn University of California, San Francisco, CA, USA
Maria Blasco Spanish National Cancer Center, Madrid, Spain
Vilhelm A. Bohr National Institute on Aging, NIH, Baltimore, MD, USA
William M. Bonner NCI, NIH, Bethesda, MD, USA
Robert M. Brosh, Jr. National Institute on Aging, NIH, Baltimore, MD, USA
Anne Brunet Stanford University, Stanford, CA, USA
Titia de Lange Rockefeller University, NY, NY, USA
Ronald A. DePinho Dana-Farber Cancer Institute, Boston, MA, USA
Lawrence A. Donehower Baylor College of Medicine, Houston, TX, USA
Caleb E. Finch University of Southern California, Los Angeles, CA, USA
Toren Finkel National Institutes of Health, Bethesda, MD, USA
Claudio Franceschi University of Bologna, Bologna, Italy
David Gems Institute of Healthy Ageing, University College London, UK
Vera Gorbunova University of Rochester, Rochester, NY, USA
Myriam Gorospe National Institute on Aging, NIH, Baltimore, MD, USA
Leonard Guarente MIT, Cambridge, MA,USA
Andrei Gudkov Roswell Park Cancer Institute, Buffalo, NY, USA
Michael Hall University of Basel, Basel,Switzerland
Philip Hanawalt Stanford University, CA, USA
Nissim Hay University of Illinois at Chicago, Chicago, IL, USA
Siegfried Hekimi McGill University, Montreal, Canada
Stephen L. Helfand Brown University, Providence, RI, USA
Jan H.J. Hoeijmakers Erasmus MC, Rotterdam, Netherlands
Stephen P. Jackson University of Cambridge, Cambridge, UK
Pankaj Kapahi Buck Institute, Novato, CA, USA
Jan Karlseder The Salk Institute, La Jolla, CA, USA
Cynthia Kenyon University of California San Francisco, San Francisco, CA, USA
Guido Kroemer INSERM, Paris, France
Arnold Levine The Institute for Advanced Study, Princeton, NJ, USA
Michael P. Lisanti Thomas Jefferson University, Philadelphia, PA, USA
Lawrence A. Loeb University of Washington, Seattle, WA, USA
Valter Longo University of Southern California, Los Angeles, CA USA
Gerry Melino University of Rome, Rome, Italy
Andre Nussenzweig National Cancer Institute, NIH, Bethesda, MD, USA
William C. Orr Southern Methodist University, Dallas, TX, USA
Heinz D. Osiewacz Goethe University Frankfurt, Frankfurt, Germany
Daniel S. Peeper The Netherlands Cancer Institute, Amsterdam, Netherlands
Thomas Rando Stanford University School of Medicine, Stanford, CA, USA
Igor B. Roninson Ordway Research Institute, Albany, NY, USA
Michael R. Rose University of California, Irvine, CA, USA
K Lenhard Rudolph Medical School Hannover, Hannover, Germany
Paolo Sassone-Corsi University of California, Irvine, CA, USA
Manuel Serrano Spanish National Cancer Research Center, Madrid, Spain
Norman E. Sharpless University of North Carolina, Chapel Hill, NC, USA
Vladimir P. Skulachev Moscow State University, Moscow, Russia
Mark A. Smith Case Western Reserve University, Cleveland, OH, USA
Sally Temple New York Neural Stem Cell Institute, Albany, NY, USA
George Thomas University of Cincinnati, Cincinnati, OH, USA
Jonathan L. Tilly Massachusetts General Hospital, Boston, MA, USA
John Tower University of Southern California, Los Angeles, CA, USA
Eric Verdin University of California, San Francisco, CA, USA
Jan Vijg Albert Einstein College of Medicine, Bronx, USA
| 
刊名字顺( Alphabetical List of Journals):
返回页首 